trial · primary record
Biopsy
Breast Carcinoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 24 |
| Primary completion | 2028-09-05 |
| Primary endpoint | Maximum tolerated dose (MTD) of the M5A-IL2 immunocytokine (M5A-ICK) |
| Registry ID | NCT06130826 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:00.995Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06130826
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.